(Total Views: 637)
Posted On: 01/03/2020 1:41:08 PM
Post# of 72448
BP companies are interested in the oral brilacidin trial starting soon.
If successful trial, and possible deal talks occur, it would appear everything
is on the table, other B indications (ABSSSI, OM) and K in terms of IPIX point
of view.
A BP wanting to cut a deal on an oral IBD pill, should be advised by IPIX that
any BP considering a deal for all IPIX assets will get stronger consideration
regarding the oral IBD pill.
In other words,
BP A only interested in oral B-IBD pill at say 3xxx dollar amount
BP B interested in oral IBD pill at say 2.6xxx dollar amount (less than BP A B-IBD offer)
but BP B also interested in K, ABSSSI, BOM at say 2.4xx dollar amount
Well then, BP B will gain access to oral B-IBD (even at a lower offer than BP A),
because they extended themselves to bid on all other assets in the portfolio.
If successful trial, and possible deal talks occur, it would appear everything
is on the table, other B indications (ABSSSI, OM) and K in terms of IPIX point
of view.
A BP wanting to cut a deal on an oral IBD pill, should be advised by IPIX that
any BP considering a deal for all IPIX assets will get stronger consideration
regarding the oral IBD pill.
In other words,
BP A only interested in oral B-IBD pill at say 3xxx dollar amount
BP B interested in oral IBD pill at say 2.6xxx dollar amount (less than BP A B-IBD offer)
but BP B also interested in K, ABSSSI, BOM at say 2.4xx dollar amount
Well then, BP B will gain access to oral B-IBD (even at a lower offer than BP A),
because they extended themselves to bid on all other assets in the portfolio.
(1)
(1)
